For laboratory and research use only. Not for human consumption.

Journal/Science

· 17 min read

Inside the American and European Peptide Supply Chain

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

This is a category explainer on how peptide quality is manufactured and proven. It is not a product page. It examines where these molecules are made, the regulatory frame that governs them, and the specific laboratory tests that separate a documented batch from an undocumented one.

The two-tier reality: research-grade versus pharmaceutical-grade

A peptide is a short chain of amino acids. The same fifteen-amino-acid sequence can be synthesized in two materially different worlds, and the distinction is not chemistry. It is intended use, documentation, and oversight.

Research-grade material is sold for laboratory work and is labeled "research use only" (RUO), with the explicit qualifier "not for human consumption." It carries no requirement to be made under current good manufacturing practice (cGMP), and the seller is not obligated to provide batch-specific identity, purity, or contaminant data. Pharmaceutical-grade material is a different regulatory object. Active pharmaceutical ingredients destined for compounding or clinical use are expected to be produced under cGMP and to travel with a documented analytical record. The federal compounding framework that governs the clinical channel is set out in sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.[1]

The table below summarizes the split. It is a generalization rather than a legal definition, and the regulatory column in particular is discussed in detail later.

The label alone is not a guarantee of anything. The substance of the difference lives in the documentation that travels, or fails to travel, with a given batch.

Where peptides are manufactured

Peptides are manufactured in two distinct settings. Inside living cells they are assembled naturally on ribosomes, where amino acids are linked in the order an mRNA template specifies. For research and clinical supply they are produced synthetically, most often by solid-phase peptide synthesis in specialized chemical laboratories and regulated pharmaceutical facilities.[21] Commercial capacity is geographically concentrated, and the regulated share sits alongside a much larger unregulated flow.

Peptide synthesis is concentrated in a small number of contract development and manufacturing organizations (CDMOs). According to peptide-CDMO market analysis, the top five manufacturers hold roughly 40% of the market, with Bachem the single largest at about 17%, and North America representing more than half of global CDMO capacity, Europe about a third, and China roughly nine percent.[2]

The named Western players are concrete and locatable. Bachem operates its largest GMP peptide hub in Bubendorf, Switzerland, alongside US sites in Vista and Torrance, California.[3] AmbioPharm has manufactured peptide APIs in North Augusta, South Carolina since 2005, with a global footprint exceeding 463,000 square feet across its US and Shanghai operations and a publicly announced North Augusta expansion of nearly $119 million.[4] PolyPeptide runs a 120,000-square-foot GMP facility in Torrance, California, repeatedly inspected by the FDA, plus a site in San Diego.[5] CordenPharma operates a large-scale peptide facility in Boulder, Colorado, with development sites in Switzerland and Germany, and has announced roughly €900 million in peptide-platform expansion.[6]

That regulated capacity sits alongside a very different flow of material. China is a dominant supplier of pharmaceutical starting material, and the trade has grown sharply. US customs records show that American imports of hormone and peptide compounds from China nearly doubled in 2025, climbing to $328 million in the first nine months of the year against $164 million the year prior.[7] The broader dependence is structural rather than incidental. Brookings analysis indicates that Chinese-made active ingredients are present in roughly a quarter of the drug volume sold in the United States. That dependence deepens once the reliance of India, the largest supplier of finished drugs to the US market, on Chinese starting materials is counted.[8] Much of the consumer-facing peptide trade moves outside the regulated channel entirely, sourced directly from Chinese factories and sold cheaply with no batch testing attached. Bloomberg's Odd Lots documented this grey market in detail in December 2025.[9]

Peptide manufacturers in the USA

Several regulated contract manufacturers synthesize peptide active pharmaceutical ingredients on US soil under current good manufacturing practice. The named domestic sites are concrete and locatable:

These are pharmaceutical-grade API manufacturers rather than consumer brands, and their output is the regulated material described above: synthesized under inspection and capable of traveling with a batch-specific certificate of analysis. Made-in-USA sourcing is therefore a documentation and accountability position rather than a chemical one, since the same sequence can in principle be synthesized anywhere.

The regulatory frame: 503A, 503B, and "research use only"

Three regulatory positions are worth separating, because they are routinely conflated.

The first is the genuine RUO position. A substance sold strictly for laboratory research, accurately labeled and not marketed for human use, sits outside the drug-approval framework. The vulnerability is that under FDA's intended-use doctrine the surrounding claims, not the label, determine whether a product is being marketed as a drug. The "research use only" line is not a shield if the rest of the presentation implies human consumption.

The second and third are the two compounding pathways created under the Drug Quality and Security Act of 2013. Section 503A covers traditional compounding by a licensed pharmacist in a state-licensed pharmacy, against a patient-specific prescription. Section 503B created the "outsourcing facility," which compounds at larger scale and must comply with cGMP and FDA inspection.[1] Whether a given bulk substance may be used in 503A compounding depends in part on FDA's interim bulks list, which sorted nominated substances into categories. Category 1 substances may be used in compounding under stated conditions while FDA evaluates them. Category 2 was the designation for substances that FDA preliminarily judged to raise significant safety concerns.[10]

This is where several well-known peptides enter the regulatory record, and the chronology is specific. In September 2023 FDA placed more than a dozen peptides into Category 2, citing significant safety concerns.[11] On April 15, 2026 FDA republished the interim 503A bulks list and announced its intent to remove twelve of those peptide substances from Category 2 within seven calendar days, while simultaneously scheduling a Pharmacy Compounding Advisory Committee (PCAC) meeting to review them.[11] The twelve include BPC-157, KPV, MOTS-C, TB-500, emideltide (DSIP), Epitalon, Semax, and five others.[11] Counsel and regulatory commentators have stressed an important point about that removal. As Frier Levitt put it, "Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A. They also remain outside the scope of the FDA's interim enforcement discretion policy."[11] The peptides were never on Category 1.

The PCAC meeting is scheduled for July 23 and 24, 2026 at FDA's White Oak campus, under public docket FDA-2025-N-6895.[12] The published split has BPC-157, KPV, TB-500, and MOTS-C reviewed on day one, and emideltide (DSIP), Semax, and Epitalon on day two.[11][12] FDA has indicated a second PCAC review of five additional peptides before the end of February 2027.[11] None of this changes what any peptide does in the body, which is not the subject of the advisory process. The committee is weighing manufacturing, characterization, and safety-data questions, which is the same lens the rest of this article uses.

What "pharmaceutical standards" means: ISO/IEC 17025 and the certificate of analysis

"Pharmaceutical standards" is a phrase that does real work only when it points at a named standard and a named document. Two are worth defining precisely.

ISO/IEC 17025 is the international standard for the competence of testing and calibration laboratories. The current edition is ISO/IEC 17025:2017. It specifies requirements for the competence, impartiality, and consistent operation of laboratories, covering qualified personnel, validated methods, calibrated equipment, participation in proficiency-testing schemes, and a quality management system, so that results are technically valid and accepted across borders.[13] A laboratory that holds 17025 accreditation for a given method has been independently assessed as competent to run that method and report a result that means what it says. Accreditation is method-specific, which is a detail that matters when reading any claim of accreditation.

A certificate of analysis (COA) is the batch-level document that records the test results for one specific lot of material: what the molecule is, how pure it is, how much actual peptide is present, and what contaminants were measured. The value of a COA depends entirely on which tests were run, which laboratory ran them, and whether the certificate is tied to the exact lot in hand. A COA that is not batch-specific describes a different batch. The sections that follow take the core assays one at a time.

Identity: confirming the molecule

The first question any analytical record must answer is whether the material is the intended molecule at all. The standard tool is mass spectrometry. Because a synthetic peptide's sequence is known in advance, the measured mass can be compared against the theoretical mass of the target sequence. A match within instrument tolerance confirms identity. A mismatch indicates a different or incorrectly assembled molecule.

The methods are well established in the analytical literature. A 2015 methods chapter by Prabhala and colleagues states plainly that "mass spectrometry (MS) is well suited for analysis of the identity and purity of synthetic peptides," and describes both MALDI-TOF-MS and LC-MS procedures for the purpose.[14] For sequence-level confirmation rather than intact-mass confirmation, tandem MS (MS/MS) fragmentation resolves the order of residues.[14] Identity testing answers presence. Amount and cleanliness are separate measurements.

Purity: HPLC, and what a purity percentage does and does not tell

Purity is most commonly measured by reversed-phase high-performance liquid chromatography (RP-HPLC). The sample is pushed through a column that separates components by how strongly each interacts with the stationary phase. The target peptide elutes as a peak, and impurities, including closely related sequences such as deletion or truncation products, elute as separate peaks. Purity is reported as the area of the main peak as a percentage of total peak area. A validated example in the peer-reviewed record is a 2017 RP-HPLC method for the synthetic peptide eptifibatide acetate, developed on a C18 column with an acetonitrile, water, and trifluoroacetic acid mobile phase and UV detection, validated per ICH guidelines, with reported accuracy of 96.4 to 103.8%.[15]

A purity percentage carries two important limits. First, it is detector-dependent and method-dependent. A figure of "99% by HPLC" describes what that specific method, at that wavelength, was able to separate and see, and a co-eluting impurity or one that does not absorb at the chosen wavelength can be undercounted. Second, purity is a ratio rather than an absolute quantity. It says nothing about how much peptide is in the vial, which is the next measurement.

Net peptide content and water content

Total vial mass is not all peptide. A lyophilized (freeze-dried) peptide also contains bound water, residual synthesis salts such as the acetate or trifluoroacetate counter-ion, and any excipients. Net peptide content is the fraction of the total mass that is the peptide itself. A vial can report high HPLC purity and still contain meaningfully less peptide by weight than the gross mass implies, because purity and content answer different questions.

Water is a measurable component, determined by Karl Fischer titration, a chemical method that reacts specifically with water and is the reference technique described in USP General Chapter <921> Water Determination.[16] For lyophilized pharmaceutical products, USP guidance puts target residual moisture below roughly one to two percent by weight.[16] USP has separately published reference-standard work addressing the quality characterization of synthetic peptide therapeutics, including content and impurity considerations.[17] Net peptide content and water content together establish how much active material a documented batch actually contains, which neither identity nor purity testing reports.

Contaminants: endotoxin and heavy-metal testing

For any material intended to be sterile, two contaminant classes carry specific testing regimes.

Bacterial endotoxins are lipopolysaccharide fragments from the cell walls of gram-negative bacteria, and they are pyrogens, meaning they can provoke a febrile response if introduced into the bloodstream. They are heat-stable and are not removed by ordinary sterilization, so they are measured directly. The standard assay is the Limulus amebocyte lysate (LAL) test, described in USP General Chapter <85> Bacterial Endotoxins Test, which the FDA recognizes for parenteral products that contact blood or cerebrospinal fluid.[18][19] Heavy-metal content is the second class, a check on elemental impurities that can carry over from reagents, catalysts, or equipment. Sterility itself, the absence of viable microorganisms, is a further and separate test, addressed in USP General Chapter <71> Sterility Tests and governed for sterile compounding by USP General Chapter <797>.[20]

These contaminant tests are the part of the analytical record that bears most directly on whether a sterile preparation was made and handled under controlled conditions, and they are routinely absent from undocumented material.

How to read a certificate of analysis, and what it cannot tell

A complete COA for an injectable-grade peptide typically reports identity (mass spectrometry), purity (HPLC, with the percentage and method stated), net peptide content, water content (Karl Fischer), and contaminant results (endotoxin, heavy metals, and where applicable sterility). The accrediting standard for the laboratory, such as ISO/IEC 17025 for the relevant methods, indicates whether the testing body has been independently judged competent.[13]

Three limits are worth stating directly, because a COA is often read as proving more than it does.

Most fundamentally, a certificate of analysis is a manufacturing and quality document. It speaks to what a molecule is and how cleanly it was made. It does not speak to what that molecule does in a human body. That is a clinical question, answered, if at all, by the published research record at whatever evidence tier exists, and for many studied peptides that tier is preclinical or animal-model rather than confirmed human data.

Why American and European sourcing matters

The case for US and EU sourcing is not patriotic and it is not about chemistry, since the same sequence can in principle be synthesized anywhere. It is about the documentation chain and who can be held to it.

A regulated Western CDMO operates inside an inspection regime. Its facilities are subject to FDA or comparable European inspection, its methods can be run in ISO/IEC 17025-accredited laboratories, and its output can travel with a batch-specific COA whose every line is traceable to an accountable party.[1][13] Material that moves through the grey market typically carries none of this. It is sourced for price, sold without batch testing, and accompanied by no accountable analytical record, which is precisely the gap the import-growth and grey-market reporting describes.[7][9] The difference between the two is not a marketing distinction. It is the presence or absence of a verifiable answer to the question of what is actually in the vial.

This is the model a small number of US and EU-sourced platforms have organized around. FeelGood is one example of that approach, building its sourcing on US and EU manufacturing with batch-specific ISO 17025 certificates, HPLC purity, mass-spectrometry identity, and contaminant testing rather than undocumented supply. The point of the model is not what any individual peptide is claimed to do. It is that every claim about the material itself can be checked against a primary document. In a market where most of the supply cannot be checked at all, a checkable supply chain is the entire distinction.

Frequently asked questions

What is the difference between research-grade and pharmaceutical-grade peptides?

The difference is intended use, manufacturing standard, and documentation, not the underlying chemistry. Research-grade material is labeled for laboratory use only and carries no requirement to be made under current good manufacturing practice or to ship with batch test data. Pharmaceutical-grade material is governed by the federal compounding framework in FD&C Act sections 503A and 503B, is expected to meet cGMP or applicable USP standards, and travels with a batch-specific certificate of analysis.[1]

Where are most research peptides manufactured?

Manufacturing is concentrated in contract development and manufacturing organizations. By market-share analysis the largest is Bachem at roughly 17%, the top five hold about 40%, and North America accounts for more than half of global CDMO capacity, with Europe about a third and China roughly nine percent.[2] At the same time, a large volume of consumer-facing peptide material is sourced outside that regulated channel, much of it from China.[7][9]

How much of the US peptide supply comes from China?

A precise share of the consumer peptide supply is not established in public data, and figures vary by what is being counted. What primary reporting does show: US imports of hormone and peptide compounds from China nearly doubled in 2025, reaching $328 million in the first nine months.[7] More broadly, Brookings analysis indicates Chinese-made active ingredients are present in roughly a quarter of US drug volume. That dependence deepens once India's own reliance on Chinese starting materials is counted.[8] The frequently repeated "roughly 90%" figure for the grey-market consumer channel circulates widely but is best treated as an industry estimate rather than a documented statistic.

What does ISO/IEC 17025 accreditation mean for peptide testing?

ISO/IEC 17025:2017 is the international standard for the competence of testing and calibration laboratories. Accreditation to it means an independent body has assessed the laboratory as competent to perform a specified method and report a valid result, based on qualified personnel, validated methods, calibrated equipment, and a quality system.[13] Accreditation is method-specific, so a meaningful claim names the methods it covers rather than asserting accreditation in the abstract.

What does a peptide certificate of analysis prove, and what can it not tell?

A certificate of analysis records the test results for one specific batch: identity by mass spectrometry, purity by HPLC, net peptide content, water content, and contaminant results such as endotoxin. It proves what the molecule is and how cleanly that lot was made. It cannot tell what the molecule does in a human body, that is a clinical question answered by the research record. It also describes only the lot it names and only the tests actually run, so an omitted test is not a passing result.

How is peptide purity measured by HPLC?

Reversed-phase HPLC separates the components of a sample by how strongly each interacts with the column. The target peptide and its impurities elute as distinct peaks, and purity is reported as the main peak's area divided by total peak area, expressed as a percentage. A validated published example is a 2017 RP-HPLC method for eptifibatide acetate on a C18 column, validated per ICH guidelines.[15] The figure is method-dependent and is a ratio, so it does not by itself indicate how much peptide is in the vial.

What is the FDA 503A status of these peptides, and what is the July 2026 PCAC review?

Several peptides, including BPC-157, KPV, MOTS-C, and Epitalon, were placed in Category 2 of FDA's interim 503A bulks list in September 2023, the category for substances preliminarily judged to raise significant safety concerns.[11] On April 15, 2026 FDA announced its intent to remove twelve of them from Category 2 and scheduled a Pharmacy Compounding Advisory Committee meeting for July 23 and 24, 2026 under docket FDA-2025-N-6895.[11][12] Regulatory counsel has emphasized that removal from Category 2 does not make these substances eligible for 503A compounding and does not place them within FDA's enforcement-discretion policy.[11]

Are any research peptides made in America?

Yes. Multiple regulated CDMOs synthesize peptide APIs on US soil under cGMP, including AmbioPharm in North Augusta, South Carolina, PolyPeptide in Torrance and San Diego, California, Bachem in Vista and Torrance, California, and CordenPharma in Boulder, Colorado.[3][4][5][6] US and EU sourcing is a documentation and accountability position: material from these facilities can travel with batch-specific, independently testable records, which grey-market material generally does not.

Footnotes

[1] U.S. Food and Drug Administration. "Human Drug Compounding" and "FD&C Act Provisions that Apply to Human Drug Compounding" (sections 503A and 503B; Drug Quality and Security Act of 2013). https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding

[2] Peptide CDMO market-share analysis (top-five concentration ~40%, Bachem ~17%, North America >50% of capacity, Europe ~33%, China ~9%), as compiled in industry market reporting, 2024-2026. https://www.openpr.com/news/3711026/peptide-cdmo-market-growth-forecast-bachem-polypeptide

[3] Bachem. "Our Locations" (Bubendorf, Switzerland GMP hub; Vista and Torrance, California, US sites). https://www.bachem.com/about-bachem/our-locations/

[4] AmbioPharm. "Peptide Manufacturing Facilities" (North Augusta, South Carolina; founded 2005; >463,000 sq ft global footprint including Shanghai) and reporting on the ~$119 million Aiken County expansion. https://www.ambiopharm.com/about-us/manufacturing-facilities/ ; https://www.scbio.org/ambiopharm-expanding-aiken-county-operations-with-nearly-119-million-investment-202-new-jobs/

[5] PolyPeptide. "San Diego and Torrance, USA" manufacturing sites (120,000 sq ft GMP facility, Torrance; multiple FDA inspections). https://www.polypeptide.com/contacts/manufacturing-sites/san-diego-and-torrance-usa/

[6] CordenPharma. "CordenPharma Expanding GMP Peptide Manufacturing in Colorado" (Boulder, CO large-scale site; Switzerland and Germany development sites) and the ~€900 million peptide-platform expansion announcement. https://cordenpharma.com/articles/cdmo_expands_us_peptide_manufacturing_capacity-2-2-2/ ; https://cordenpharma.com/articles/press-release-cordenpharma-invests-900-million-euros-in-transformational-peptide-platform-expansion-in-usa-and-europe/

[7] gZERO Media (GZERO/Eurasia Group). "How China is supplying America's 'biohacking' craze" (US imports of hormone and peptide compounds from China climbed to $328 million in the first nine months of 2025, up from $164 million the prior year; citing US customs records). https://www.gzeromedia.com/news/analysis/how-china-is-supplying-americas-biohacking-craze

[8] Brookings Institution. "US drug supply chain exposure to China" (analysis of FDA data; ~13% of US-consumed drugs manufactured in China, rising once reliance via India's key starting materials is counted). https://www.brookings.edu/articles/us-drug-supply-chain-exposure-to-china

[9] Bloomberg, "Odd Lots." "The Booming Business of Chinese Peptides" (December 19, 2025; grey-market peptide sourcing direct from Chinese factories). https://www.bloomberg.com/news/audio/2025-12-19/chinese-peptides-are-a-booming-business-in-the-us

[10] U.S. Food and Drug Administration. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act" (interim policy; Category 1 vs Category 2 framework). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act

[11] Frier Levitt. "FDA to Remove 12 Peptides from the Category 2 'Do Not Compound' List" (September 2023 Category 2 designation citing immunogenicity, impurities, limited human data; April 15, 2026 republished interim 503A bulks list removing twelve peptides from Category 2; PCAC day-one/day-two split; second review before February 2027; "Removal from Category 2 does not render these bulk drug substances eligible for compounding under section 503A..."). https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/

[12] U.S. Food and Drug Administration / Federal Register. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments" (July 23-24, 2026, White Oak; docket FDA-2025-N-6895). https://www.federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request

[13] International Organization for Standardization. ISO/IEC 17025:2017, "General requirements for the competence of testing and calibration laboratories." https://www.iso.org/standard/66912.html

[14] Prabhala BK, Mirza O, Højrup P, Hansen PR. "Characterization of Synthetic Peptides by Mass Spectrometry." Methods Mol Biol. 2015;1348:77-82. PMID: 26424265. https://pubmed.ncbi.nlm.nih.gov/26424265/

[15] Bavand Savadkouhi M, Vahidi H, Ayatollahi AM, Hooshfar S, Kobarfard F. "RP-HPLC Method Development and Validation for Determination of Eptifibatide Acetate in Bulk Drug Substance and Pharmaceutical Dosage Forms." Iran J Pharm Res. 2017 Spring;16(2):490-497. PMID: 28979304. https://pubmed.ncbi.nlm.nih.gov/28979304/

[16] U.S. Pharmacopeia. General Chapter <921> "Water Determination" (Karl Fischer titration as reference method; lyophilized-product residual moisture targets), as described in USP-aligned analytical guidance. https://www.usp.org/

[17] U.S. Pharmacopeia. "Reference Standards to Support Quality of Synthetic Peptide Therapeutics," Pharmaceutical Research (2023);40:1317-1328. https://www.usp.org/sites/default/files/usp/document/our-work/biologics/reference_standards_to_support_quality_of_synthetic_peptide_therapeutics.pdf

[18] U.S. Pharmacopeia. General Chapter <85> "Bacterial Endotoxins Test" (Limulus amebocyte lysate methods). Referenced via USP/FDA endotoxin guidance.

[19] U.S. Food and Drug Administration. "Bacterial Endotoxins/Pyrogens" (Inspection Technical Guide; LAL test for parenteral products). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-technical-guides/bacterial-endotoxinspyrogens

[20] U.S. Pharmacopeia. General Chapter <797> "Pharmaceutical Compounding: Sterile Preparations" and General Chapter <71> "Sterility Tests." https://www.usp.org/compounding/general-chapter-797

[21] Bachem. "Peptide Manufacturing: Step-By-Step Guide" (chemical synthesis of peptides by sequential coupling of amino acids; solid-phase peptide synthesis in regulated facilities). https://www.bachem.com/knowledge-center/peptide-manufacturing-step-by-step-guide/

We publish the science, not a sales pitch.

The FeelGood Journal is a citation-led editorial library on peptide research, manufacturing standards, and the regulatory landscape, written for readers who want primary sources.

Back to the Journal